Cancer stem cells initiate and perpetuate tumor growth, and are more resistant to chemotherapy and radiation therapies. Cancer stem cells are the tumor cells that metastasize, causing cancer to spread throughout the body.
Stemcentrx therapies are engineered to target cancer stem cells, subsequently delivering a potent drug that can kill them. We believe that targeting and eliminating cancer stem cells will enable long-term patient survival.
Cancers occur in many forms and our data indicate each cancer subtype should be targeted specifically. Stemcentrx has discovered and is developing drugs for a number of cancer subtypes. We are also developing companion diagnostic tests that can be used to identify patients most likely to benefit from those drugs.
Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor Initiating Cells to Result in Sustained Tumor RegressionsRead more
Initiation and Characterization of Small Cell Lung Cancer Patient-Derived Xenografts from Ultrasound-Guided Transbronchial Needle AspiratesRead more
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in crecurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 studyRead more